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Plasmodium falciparum liver stage antigen-1 is
cross-linked by tissue transglutaminase
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Abstract
Background: Plasmodium falciparum sporozoites injected by mosquitoes into the blood rapidly enter liver
hepatocytes and undergo pre-erythrocytic developmental schizogony forming tens of thousands of merozoites per
hepatocyte. Shortly after hepatocyte invasion, the parasite starts to produce Liver Stage Antigen-1 (LSA-1), which
accumulates within the parasitophorous vacuole surrounding the mass of developing merozoites. The LSA-1
protein has been described as a flocculent mass, but its role in parasite development has not been determined.
Methods: Recombinant N-terminal, C-terminal or a construct containing both the N- and C- terminal regions
flanking two 17 amino acid residue central repeat sequences (LSA-NRC) were subjected to in vitro modification by
tissue transglutaminase-2 (TG2) to determine if cross-linking occurred. In addition, tissue sections of P. falciparum-
infected human hepatocytes were probed with monoclonal antibodies to the isopeptide ε-(g-glutamyl)lysine cross-
bridge formed by TG2 enzymatic activity to determine if these antibodies co-localized with antibodies to LSA-1 in
the growing liver schizonts.
Results: This study identified a substrate motif for (TG2) and a putative casein kinase 2 phosphorylation site within
the central repeat region of LSA-1. The function of TG2 is the post-translational modification of proteins by the
formation of a unique isopeptide ε-(g-glutamyl)lysine cross-bridge between glutamine and lysine residues. When
recombinant LSA-1 protein was crosslinked in vitro by purified TG2 in a calcium dependent reaction, a flocculent
mass of protein was formed that was highly resistant to degradation. The cross-linking was not detectably affected
by phosphorylation with plasmodial CK2 in vitro. Monoclonal antibodies specific to the very unique TG2 catalyzed
ε- lysine cross-bridge co-localized with antibodies to LSA-1 in infected human hepatocytes providing visual
evidence that LSA-1 was cross-linked in vivo.
Conclusions: While the role of LSA-1 is still unknown these results suggest that it becomes highly cross-linked
which may aid in the protection of the parasite as it develops.
Background
The liver stage antigen-1 (LSA-1) is one of the few
antigens known to be specifically expressed during the
pre-erythrocytic liver stage of Plasmodium falciparum
[1]. Studies of human immunity following exposure to
radiation-attenuated sporozoites, as well as exposure to
naturally transmitted parasites, have consistently asso-
ciated protection with a specific LSA-1 immune
response, making LSA-1 an attractive vaccine candidate
[2-8]. LSA-1 has undergone several clinical trials. Firstly
the sequence of the non-repeat regions were as part of a
recombinant pox virus expressing LSA-1 and six other
candidate malaria vaccine antigens [9] that induced
LSA-1 cellular immune responses [10]. Later it was
included as one of five antigens encoded by DNA plas-
mids that induced boostable cellular responses [11].
Most recently, as a recombinant protein combined with
AS01 or AS02 adjuvant [12] it induced high titer anti-
body and CD4 + T cells that secreted IL-2 and inter-
feron-gamma although it did not induce protection
against an experimental P. falciparum sporozoite chal-
lenge model in humans [13].
Although LSA-1 was first identified in 1987 [14], elu-
cidation of the functional role of LSA-1 has yet to
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occur. Plasmodium falciparum liver-stage parasites are
difficult to study, as the only primate model uses chim-
panzees [15] and, in vivo and liver stages develop in
only a few infected hepatocytes. Full liver-stage develop-
ment of P. falciparum occurs in vitro in primary hepato-
cyte cultures from Aotus and Saimiri monkeys [16] and
a human hepatocyte cell line has recently been devel-
oped that allows P. falciparum infection and develop-
ment, but again infectivity is extremely low and
obtaining protein has thus far proven impossible [17].
This paucity of infected cells, combined with the diffi-
culty of their isolation, results in an inability to bio-
chemically study native liver-stage material.
LSA-1 is a 230 kDa protein characterized by a cen-
tral repeat region containing 86 repeats of the 17-
amino-acid sequence EQQSDLEQERLAKEKLQ or
minor variations thereof [18]. Flanking these repeats are
a non-repetitive 154 residue N- terminal region and a
280 residue C-terminal region [18,19]. The sequence of
LSA-1 repeat and non-repeat regions is highly con-
served across strains of P. falciparum [19] suggesting a
crucial role during liver schizogony [19]. Of interest is
the finding that a peptide form the LSA-1 N-terminal
region binds to hepatic cells and to HLA-DRb1*1101
[20], which is consistent with the induction of CD4 + T
cell responses in clinical trials [11,21]. Analysis of
infected primate liver sections probed with antibodies
against LSA-1 has shown that synthesis of LSA-1 begins
soon after sporozoite invasion and that the protein
accumulates throughout the liver stage development
[22,23]. From three days post infection, LSA-1 is detect-
able in the parasitophorous vacuole (PV), which is deli-
neated by the inner plasmalemma and the outer
parasitophorous vacuole membrane (PVM) of the
infected hepatocyte, and surrounds the developing mer-
ozoites as part of a “flocculent mass” [23]. A similar
flocculent mass has been observed in Plasmodium ber-
ghei and Plasmodium vivax liver stages [22,24-26], but
are not recognized by LSA-1 antibodies. At a later stage,
LSA-1 appears to infiltrate the spaces between the pseu-
docytomeres of the developing schizonts as the plasma-
lemma forms deep invaginations into the parasite
cytoplasm [22,23]. Eventually LSA-1 is localized around
the cytomeres just before individualization of the mero-
zoites. Upon hepatocyte rupture the merozoites are
released within the flocculent mass into the liver sinu-
soid where erythrocyte invasion occurs [27-30].
These observations suggest that LSA-1 is not a soluble
protein but has some sort of biochemically-induced
structure. LSA-1 central repeat amino acid sequences
contain multiple copies of the tripeptide EQQ that is a
common substrate for transglutaminases. Transglutami-
nases, enzymes found in mammals but not protozoa,
form ε-(g-glutamyl)lysine bridges between the acyl
donor side chain of glutamine and acyl acceptor side
chain of lysine, covalently cross-linking proteins as
shown in Figure 1A. Tissue transglutaminase type II
(TG2) is a multi-functional enzyme which has been
implicated in a range of biological processes including
cell death, extracellular matrix stabilization and cell
signaling [31-34]. Amongst a range of diseases, TG2
has been implicated as having a role in degenerative
conditions of the liver such as hepatitis and Budd-
Chiari syndrome [35-39]. Nardacci et al [37] demon-
strated that a TG2 knockout mouse exhibited impaired
liver regeneration after injury and that TG2 is rapidly
up-regulated after hepatitis-induced liver damage in
human patients.
As purified native protein was not available, recombi-
nant LSA-1 using LSA-NRC that contains the N- and C
terminal regions and two repeats [12] was tested as a
substrate for TG2 in vitro. The data presented here sug-
gests that native P. falciparum LSA-1 exhibits TG2-
mediated cross-linking in vivo that was confirmed by
demonstrating that LSA-1 is similarly cross-linked using
an in vivo mouse-human chimeric model in which
P. falciparum sporozoites develop into liver stages [40,41].
A physiological role for this cross-linking is proposed.
Methods
Production of recombinant LSA N-terminal (LSA-NRC-N)
and C-terminal (LSA-NRC-C) proteins
Using the recombinant LSA-1 vaccine candidate construct
LSA-NRC [12] as a template, the N- and C- terminal
regions were amplified through PCR using the
primers GTGGATCCATGGGTACCAACAGCG (N-term
fwd); GCGGCCGCAGCAGCTTTTTCTTC (N-term rev);
GTGGATCCCGCAAGGCTGACAC (C-term fwd);
GCGGCCGCAAGCTTCATAAGTATTTAG (C-term
rev). The PCR products were cloned into the pETK
expression vector using the compatible BamHI/NotI
restriction sites (underlined) [12]. Expression and purifica-
tion was performed as described for LSA-NRC [12].
Figure 1 TG2 cross-linking reaction. A. In the presence of
calcium, TG2 forms an isopeptide bond between g-carbonyl group
of a glutamine residue and the ε-amino group of a lysine residue.
Major repeat of LSA-1. B. TG2 and CK2 substrate motifs are indicated
by lines.
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Recombinant TG2 assay (PAGE analysis)
A 500 μl reaction mixture containing 100 mM Tris-HCl
pH 6.0; 500 mM NaCl; 10 mM CaCl2; 1 mM DTT; 150
μg/ml target protein (LSA-NRC full length, LSA-NRC
N-term or LSA-NRC C-term) and 100 μg/ml TG2, was
incubated at 37°C for up to 2 h. Small samples (50 μl)
were taken at appropriate timepoints. Reaction samples
were stopped by the addition of 50 μl of 4× SDS loading
dye and stored at 4°C. 25 μl protein samples were sepa-
rated on precast 4-12% gradient SDS PAGE (Invitrogen,
Carlsbad, CA) and stained with Coomassie blue.
TG2 assay (ELISA Analysis)
An assay based upon Lilley et al. [42] was developed to
test LSA-1 cross-linking in vitro. LSA-NRC was bound
to 96 well plates at a concentration of 0.20 μg/ml in
50 mM Na2CO3 at pH 9.8 for 1 h at 37°C. Wells were
then blocked for 1 h at 37°C with 200 μl of a solution
containing 0.5% boiled casein; 1% Tween 80; 50 mM
Na2CO3 pH 9.8. Wells were washed twice with 1×PBS
pH 7.4; 0.05% Tween 80 and twice with H2O. Reactions
were set up with 100 mM Tris-HCl pH 6.0; 5 mM
CaCl2; 10 mM DTT; 5 μg/ml biotinylated LSA-NRC
(produced using the EZ-link NHS-biotin labeling kit,
Pierce, Rockford, IL); and up to 2 μg/ml TG2 in a total
reaction volume of 50 μl. Reactions were incubated for
1 h at 37°C. Wells were washed twice with 1×PBS pH
7.4; 0.05% Tween 80 and twice with H2O. Plates were
then incubated with 50 μl of 1:10,000 dilution of peroxi-
dase-bound neutravidin; 100 mM Tris-HCl, pH 8.5;
0.5% boiled casein for 1 h at room temp. Wells were
washed three times with 1×PBS, pH 7.4; 0.05% Tween
80 and twice with H2O. Developing was performed
using 100 μl of KPL ABTS peroxidase substrate (KPL
Inc., Gaithersburg MD) for 60 min. Development was
stopped with 100 μl 1% SDS and samples were read at
405 nm.
Recombinant TG2 cell extract assay (Western analysis)
To assess whether LSA could act as a TG2 substrate an
in vitro assay was developed with cell extracts from both
human neuroblastoma cell lines either not expressing
(SK-N-BE-2), or over-expressing (TGA), hTG2 [43]. For
the cell free assay, 500 ng of LSA protein were incu-
bated with 250 μg of cell extracts in 50 mM Tris-HCl,
pH 8.3, 30 mM NaCl, 10 mM DTT, 15 mM CaCl2 at
37°C, in a final volume of 50 μl. Every 5 min 10 μl of
the reaction were taken and after addition of 2 mM
EGTA and NuPAGE sample buffer, samples were boiled
and separated on 4-12% NuPAGE gel (Invitrogen) prior
to analysis by Western blot. Blots were probed with
1:1,000 dilution of anti-LSA polyclonal mouse primary
antibody and 1:1,000 dilution of an HRP-conjugated
goat anti-mouse secondary antibody.
Reversed-phase HPLC analysis
RP-HPLC was performed using a Waters modular
HPLC system consisting of two Waters 510 fluid
pumps, Waters 717plus autoinjector, Waters 2487 UV
detector, Waters system interface module and a Waters
DeltaPak C18-300A column. Instrument control, data
acquisition and evaluation were performed using Waters
Millenium32 software. Buffer A comprised 0.05% (v/v)
trifluoracetic acid in H2O, whereas buffer B comprised
0.05% (v/v) trifluoroacetic acid in acetonitrile. Bound
proteins were eluted using a linear gradient of 10-100%
buffer B over 30 min at a flow rate of 1 ml/min. Peaks
were analysed by matrix-assisted laser desorption ioniza-
tion-time of flight mass spectrometry (Voyager biospec-
trometry RP system; Applied Biosystems) with a
a-cyano-4-hydroxycinnamic acid (peptides) or sinapinic
acid (protein) matrix.
Mouse/human chimeric liver immunofluorescence assays
All experiments utilized sporozoites of the NF54 strain of
P. falciparum. Sporozoites were reared in Anopheles ste-
phensi mosquitoes and were isolated by hand dissection or
by a discontinuous Renografin gradient [44] in Medium
199 (Gibco, Grand Island, NY) with 5% foetal calf serum.
The generation of chimeric mice has been previously
described [40,41]. Briefly, SCID mice, homozygous for the
urokinase type plasminogen activator transgene (SCID
Alb-uPA), were inoculated intrasplenically with 1 × 106
human hepatocytes. At 6 wks post-transplant, serum ana-
lysis for human alpha one antitrypsin (hAAT) by ELISA
was performed to determine the success of the transplan-
tation. Mice that demonstrated >25 μg/ml hAAT were
then used for infection with P. falciparum sporozoites.
Mice were cared for by the University of Alberta Health
Sciences Laboratory Animal Services according to the
guidelines of the Canadian Council on Animal Care and
under protocols approved by the University of Alberta
Faculty of Medicine and Dentistry Health Sciences
Laboratory Animal Ethics Committee. Additionally, the
experiments reported here were carried out according to
the principles set forth in the “Guide for the Care and Use
of Laboratory Animals” [45]
Infection with sporozoites and tissue collection
Chimeric mice received an intravenous tail vein injec-
tion of 1-1.5 × 106 P. falciparum sporozoites and were
subsequently euthanized by CO2 overdose at several dif-
ferent timepoints post-infection and their livers removed
for cryosectioning. Livers were rinsed in PBS, the lobes
cut into separate pieces and frozen in Tissue-Tek O.C.
T. compound (Miles Scientific, Naperville, IL.) using an
isopentane/liquid N2 bath. Tissue cryo-sections (7 μm)
were then cut, fixed in absolute methanol, and stored at
-80°C until used.
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Immunofluorescence assay
Slides were removed from the freezer, placed in a desic-
cator and allowed to equilibrate to room temperature.
The diluted antiserum (polyclonal rabbit anti-LSA-1
[12] or 71A3F1 and 81D1C2 monoclonal (Abcam Inc,
Cambridge, MA) antibodies) was then applied to the tis-
sue section in a volume sufficient to cover the tissue.
Slides were incubated for 30 min at 37°C in a humidity
chamber, then washed three times for 5 min with PBS
and incubated with a fluorescein conjugated IgG (Kirke-
gaard and Perry, Gaithersburg, MD) diluted 1:40 with
0.02% Evan’s blue for 30 min at 37°C. The Evan’s blue
was added to act as a counterstain to suppress any auto-
fluorescence in the tissue. The specificity of the second-
ary antibody varied depending upon the species of the
primary antibody used to stain the sections. Sections
were then washed as above and the slides mounted with
Vectashield® mounting media (Vector Labs, Burlingame,
CA). The stained slides were screened with a Nikon
Eclipse E600 epifluorescent microscope and digital
images collected with a SPOT digital camera (Diagnostic
Instruments, Inc., Sterling Hgts, MI).
CK2 phosphorylation assay
Recombinant P. falciparum CK2a (PfCK2 a) (PlasmoDB
ID PF11_0096) was cloned and expressed in E. coli as a
GST-tagged protein (Z. Holland and C. Doerig, unpub-
lished data). Kinase assays were performed in a standard
reaction (30 μl) containing 15 mM Tris-HCl, pH 7.5;
15 mM MgCl2; 1.5 mM MnCl2; 10 mM b-glycerol phos-
phate; 10 mM NaF; 10 μM ATP; 0.075 MBq of [g-32P]
ATP (220 TBq/mmol; GEHealthcare), 6 μg of substrate
(LSA-NRC) and 1 μg of recombinant PfCK2a. After
30 min at 30°C, reactions were terminated by the addi-
tion of Laemmli buffer, boiled for 3 min, and separated
on a 12% SDS/polyacrylamide gel. Following staining
with Coomassie blue, the gel was dried and submitted
to autoradiography.
Results
LSA-1 contains substrate motifs for TG2 and casein
kinase II
BlastN and BlastP searches against the full-length P. fal-
ciparum LSA-1, the N-terminal, repeat and C-terminal
regions have failed to reveal the existence of homolo-
gous genes in any other organism, including all other
known Plasmodium species, except Plasmodium reiche-
nowi. Motif searches of the LSA-1 amino acid sequence
revealed that the 17-mer repeat region possesses the
properties of a glutamine acyl-donor substrate for TG2
as well as an immediately adjacent casein kinase II
(CK2) substrate motif (Figure 1B). Substrates of TG2
are wide and varied, as is the TG2 substrate motif, how-
ever, it is generally considered that proteins containing
two or more adjacent glutamines are good TG2 sub-
strates [46,47]. Additionally, for the lysine substrate,
increased specificity is seen when the residue on the
N-terminal side of the lysine is a hydrophobic amino
acid such as leucine [48].
LSA-1 is a substrate for TG2
The recombinant form of LSA-1 (LSA-NRC) contains
the N- and C- terminal regions combined with two of
the central repeats [12]. To assess whether this recom-
binant LSA-NRC could act as a TG2 substrate, LSA-
NRC was incubated in the presence of 50 μg/ml guinea
pig liver TG2 (gpTG2). gpTG2 was chosen as it is the
most widely available TG2, is widely used in TG2
assays, and is known to have a wide substrate range
[49]. Additionally, since LSA-1 is more likely to come
into contact with human TG2 (hTG2), LSA-NRC was
assessed whether it could act as a substrate for both
purified recombinant hTG2, and hTG2 in cell lysates
from a transgenic human cell line that over expresses
hTG2. Figure 2A (i and ii) clearly shows the produc-
tion of LSA-NRC multimers over time after incubation
with gpTG2 or hTG2. As time progressed a flocculent
precipitate was observed in the reaction tube which
was unable to enter the PAGE gel, as can be seen in
the tops of the wells in the late time points of Figure
2A(i and ii). The largest molecule that can be seen on
the gel is a small amount of a 214 kDa protein, which
would fit the size of an LSA-NRC tetramer. It is
assumed that multimers bigger than this precipitate
out of solution.
An increase in mobility can be seen over time for the
TG2-treated LSA-NRC monomer (Figure 2A i and 2A
ii). Incubation of LSA-NRC with TG2 (Figure 2B) in the
absence of CaCl2 did not result in any detectable cross-
linking.
Figure 2C shows a Western blot analysis of LSA-NRC
incubated with lysates of human cell line SK-N-BE(2) (i)
and its stably transfected derivative, TGA, that overex-
presses hTG2 (ii). Although a small amount of a band
that correlates to LSA-NRC dimers can be seen at time
zero in both SK-N-BE(2) and TGA lysate-treated LSA-
NRC, no further cross-linking is seen in cell lysates not
expressing hTG2, whereas in contrast several bands
attributed to LSA-NRC cross-linking are observed in
lysates containing hTG2.
To further quantify TG2 activity, an ELISA assay was
developed (based on [42]). As can be see in Figure 2D
an increasing concentration of TG2 is directly related to
an increasing level of cross-linked biotin-labeled LSA-
NRC. Figure 2D clearly illustrates that no cross-linking
occurs in the absence of either calcium or TG2,
confirming that this reaction is not autocatalytic and is
calcium dependent as is typical of TG2 reactions.
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The LSA-1 repeat region is the target Of TG2 cross-linking
To assess whether the predicted TG2 glutamine sub-
strate in the LSA-1 repeat region was in fact a TG2 sub-
strate, LSA-NRC was incubated with TG2 and a LSA-1
repeat peptide containing a single repeat unit. As can be
seen in Figure 3A, inclusion of the peptide resulted in
blocking the shift in mobility, suggesting a reduction in
intra-LSA-NRC cross-linking. Interestingly, the mobility
of LSA-NRC-peptide decreased over time suggesting
that multiple repeat peptides are being successively
crosslinked to the LSA-NRC monomer, gradually
increasing its molecular weight.
To assess the ability of the LSA-1 repeat region to
crosslink to itself, a single repeat peptide was incubated
with gpTG2. RP-HPLC analysis of the cross-linking reac-
tion showed three distinct peaks (Figure 3B). Analysis of
the peaks by MALDI-TOF MS showed that peaks 1, 2
and 3 related to the expected sizes of monomers, dimers
and trimers of the LSA repeat peptide (data not shown).
Analysis of the primary amino acid sequence of the LSA-
1 repeat peptide by Robetta Protein Structure Prediction
server [50] yielded the tertiary structure shown in Figure
3C. Of note are the lysine glutamine pairs (Gln-2/Lys-15
and Gln-3/Lys-13) that project out on either side of the
helix that could act as anti-parallel TG2 cross-linking
pairs, and thus allow the formation of multimers.
To further assess the role of TG2 cross-linking of the
LSA-1 repeats, recombinant versions of both the
N-terminal (LSA-NRC-N), and C-terminal region of
LSA-NRC (LSA-NRC-C) were produced that contained
none of the central repeats. Incubation of LSA-NRC-N
and LSA-NRC-C with gpTG2 did not result in multimers
being produced (Figure 3D i and 3D ii). However, a simi-
lar increase in mobility was seen for the monomers of
LSA-NRC-C as was seen for monomers of LSA-NRC.
CK2 phosphorylation does not affect TG2 cross-linking
The presence of multiple CK2 phosphorylation sites
(one per repeat) in the repeat region of LSA-1 suggests
the possibility of TG2 mediated cross-linking being
regulated through casein kinase 2 (CK2) phosphoryla-
tion. To test this hypothesis, a recombinant catalytic
subunit of P. falciparum CK2, PfCK2a was prepared.
Initially, to ascertain whether LSA-1 can be phosphory-
lated by CK2, LSA-NRC was incubated with [g-32P]ATP
in the presence or absence of PfCK2a. As can be seen
on the Coomassie blue stained-gel Figure 4A(i), LSA-
NRC is present in lanes 1-3, but only the lane contain-
ing LSA-NRC and active PfCK2a shows a band on the
autoradiograph indicating incorporation of 32P into the
LSA-NRC sample (Figure 4A(ii) lane 1). No bands of
this size can be seen in any of the control lanes, which
include a reaction with a kinase-mutant (K72M) of the
enzyme (Figure 4A (ii) lanes 2-4). To assess the effect of
phosphorylation on TG2 mediated LSA-NRC cross-
linking, phosphorylated and non-phosphorylated LSA-
NRC were treated with gpTG2. As can be seen in Figure
4B(i) and (ii), phosphorylation caused no detectable dif-
ference to gpTG2 under the conditions used.
LSA-1 cross-linking in vivo
Plasmodium falciparum is a human parasite and does
not develop in animals except for a few species of non-
human primates. Therefore, the isolation of infected
Figure 2 Assessment of LSA-NRC cross-linking by TG2. A. SDS
PAGE analysis of LSA-NRC samples after various times of incubation
with 100 μg/ml of either gpTG2 (i) or hTG2 (ii). * indicates the band
representing TG2 (MW - 76.6 kDa). B. SDS PAGE analysis of LSA-NRC
samples after various times of incubation with 100 μg/ml of gpTG2
in the absence of CaCl2 indicating dependence of cross-linking on
Ca+. C. Western analysis of LSA-NRC samples after incubation with
lysates of human cell line SK-N-BE(2) (i) or its stably transfected
derivative, TGA, that over-expresses hTG2 (ii). Blots were probed
with anti-LSA-NRC polyclonal antibodies. D. Plate based colorimetric
analysis of LSA-NRC TG2 mediated cross-linking. Change in
absorbance at 405 nm is shown as a function of TG2 concentration.
Open circles - hTG2; Open triangles - gpTG2; Open squares - gpTG2
in the absence of CaCl2; closed triangles - in the absence of TG2.
Error bars show variation of 3 experiments.
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hepatocytes from in vivo sporozoite infection under
normal conditions is virtually impossible. Likewise, the
in vitro tissue culture of hepatocytes that are susceptible
to sporozoite invasion is limited and does not yield suf-
ficient material for biochemical analysis. Fortunately, a
chimeric mouse model has recently been developed
wherein human livers are grown [41]. Because the
pattern of LSA-1 in developing liver schizonts is so dis-
tinctive it predicted that monoclonal antibodies specific
to the glutamine-lysine isopeptide bridge should demon-
strate the same staining pattern as anti-LSA-1 antibo-
dies. Therefore, to assess whether LSA-1 is crosslinked
in vivo, P. falciparum infected liver sections from the
chimeric mice were probed with polyclonal mouse
antibodies raised against LSA-NRC. LSA-1 is clearly
visible in infected hepatocytes at day 5 and day
6 post-infection (Figure 5A and 5B). To detect specific
glutamine-lysine isopeptide linkages created by TG2
cross-linking, two different mouse monoclonal antibodies
specific for this linkage (71A3F1 and 81D1C2) were used
to probe fixed tissue sections (Figure 5C and 5D). Fluor-
escent signal is seen across the entire infected cell in a
similar pattern to that seen with anti-LSA-1 antibodies.
In contrast, the surrounding non-infected cells used as a
control for non-parasite protein reactivity exhibit almost
no fluorescence.
Figure 3 Analysis of cross-linking site. A. PAGE analysis of LSA-NRC TG2-cross-linking in the absence (i) or presence (ii) of peptide
corresponding to the major repeat sequence of LSA-1. B. RP-HPLC analysis of a peptide corresponding to the major repeat sequence of LSA-1
before (i) and after (ii) gpTG2 treatment for 2 h at 100 μg/ml gpTG2. Position of monomers [retention time 23.3 min] (1), dimers [retention time
24.5 min] (2) and trimers [retention time 25.6 min] (3) are indicated. (ii). C. Tertiary structure of a single LSA-1 major repeat as predicted by
Robetta modeling. Arrows indicate glutamines and lysines predicted to be involved in TG2 mediated cross-linking. D. PAGE analysis of gpTG2
cross-linking of LSA-NRC-C (i) and LSA-NRC-N (ii). * indicates band formed by the gpTG2 enzyme (MW - 76.6 kDa).
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Discussion
LSA-NRC is susceptible to TG2 cross-linking by both
gpTG2 and hTG2 in vitro. As a monomer LSA-NRC is
highly soluble, but upon cross-linking, LSA-NRC rapidly
comes out of solution and is seen as a flocculent mass
under in vitro cross-linking conditions. This is consis-
tent with ultrastructural observations [19,23] that
described LSA-1 in 6 day post-infection primate liver
sections as a ‘fluffy flocculent mass’.
The presence of a potential CK2 phosphorylation site
within the LSA-1 repeat region that overlaps the TG2
cross-linking site suggested that TG2-mediated cross-
linking of LSA-1 may be regulated through CK2 phos-
phorylation. However, although this study demonstrated
that LSA-NRC is phosphorylated in vitro by CK2 of
parasite origin, this phosphorylation does not affect TG2
mediated cross-linking under our experimental condi-
tions. However, it cannot be ruled out that phosphoryla-
tion has an effect on cross-linking, but that the
proportion of phosphorylated substrate is too small in
our conditions to allow detection in the cross-linking
assay.
Tertiary structural Robetta modelling [51] predicted
that each LSA-1 repeat sequence exists as a single
a-helix resulting in an extended a-helical arrangement.
This is consistent with previous analysis of the LSA-1
repeat peptides by circular dichroism suggesting that the
repeat region of LSA-1 is an uninterrupted stretch of
a-helices reaching a length of 220 nm [19]. The a-helix
model produced by Robetta modelling in this study
showed that a Gln-Lys pair protrudes on either side of
the repeat helix. By orientating successive LSA-1 mole-
cules in opposite directions these pairs could bind to
each other forming TG2-cross-linked bonds between
molecules resulting in a flexible matrix type arrangement
as seen with the transglutaminase-mediated cross-linking
Figure 4 PfCK2a regulation of TG2 LSA-1 cross-linking. (A) PAGE
analysis of LSA-NRC incubated with PfCK2 a. Coomassie stained
samples (i). Autoradiograph of gel in (i) (ii). Lane 1 - LSA-NRC incubated
with PfCK2a; lane 2 - LSA-NRC incubated with inactivated PfCK2a; lane
3 - LSA-NRC; lane 4 - PfCK2a. (B) PAGE analysis of samples taken at
various time points from non-phosphorylated (i) and phosphorylated
(ii) LSA-NRC incubated with gpTG2.
Figure 5 P. falciparum LSA-1 in human liver hepatocytes .
P. falciparum sporozoites were injected intravenously into
transgenic, chimeric mice possessing functioning human livers. Liver
nodules were collected 5 or 6 days after injection, fixed and
sectioned. Sections containing developing parasites were probed
with antibody and detected by immunofluorescence. (A) A 5-day
infected liver section probed with mouse polyclonal sera against
LSA-NRC. (B) A 6-day infected liver treated as in (A). (C) A 6-day
infected liver probed with mAb 71A3F1 that recognizes the TG2
formed isopeptide bond between glutamine and lysine. (D) As in
(C) but using another mAb, 81D1C2, that also recognizes the TG2
isopeptide bond [52].
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of fibrin during blood clotting [52]. Incubation of the
LSA-1 repeat peptide with gpTG2 resulted primarily in
the formation of peptide dimers with very few trimers or
tetramers, indicating that the majority of cross-linking
was occurring at only one site on the peptide and that
once this is bound no further cross-linking occurs.
Further evidence indicating that the primary cross-link-
ing site is the repeat region was provided by attempts to
crosslink LSA-NRC-N and LSA-NRC-C proteins that
lack any repeats: neither of these proteins was able to
form multimers after incubation with TG2. However,
LSA-NRC-C did show an increase in mobility during
SDS-PAGE analysis suggesting that intramolecular cross-
linking was occurring and leading to speculation that
intramolecular cross-linking of the C-terminal of LSA-
NRC may be responsible for the increased mobility seen
in the full length LSA-NRC.
Obtaining human or primate livers infected with early
stages of P. falciparum is either impossible or prohibi-
tively expensive. Therefore, analysis of infected human
liver sections derived from chimeric mice infected with
P. falciparum [40,41] has proved invaluable. That TG2-
specific cross-linking does occur in vivo and that the
location of this cross-linking is closely associated with
that of LSA-1 was shown by incubating tissue sections
derived from these livers with two different monoclonal
antibodies that are specific to the very unique bond
formed by the TG2 cross-linking, the ε-(g-glutamyl)
lysine cross-bridge. While this model system does pro-
vide tissue sections for analysis, the infection rate is not
sufficient to allow purification of native LSA-1, and thus
biochemical or biophysical analysis that would show
that native LSA-1 is cross-linked by TG2. However, the
in vitro data coupled with the in vivo co-localization of
the unique ε-(g-glutamyl)lysine cross-bridge with the
LSA-1 tissue localization pattern observed strongly sug-
gests the two are associated in vivo.
This then leads to speculation as to why LSA-1 needs
to be cross-linked during infection. The internal repeat
unit of LSA-1, about 85 copies of a 17 amino acid unit
containing the TG2 substrate motif would suggest that
its function is important. A typical P. falciparum infec-
tion involves the migration of the P. falciparum sporo-
zoites through a number of liver cells prior to actually
infecting a hepatocyte and forming a parasitophorous
vacuole [53]. Cellular damage to the liver has been
shown to result in up regulation of TG2 expression in
the damaged tissue [54]. Additionally, TG2 activity has
been shown to be present in P. falciparum and Plasmo-
dium gallinaceum infected red blood cells [55]. Thus it
is likely that TG2 activity would be found at the site of
P. falciparum infection. A P. falciparum infected hepa-
tocyte experiences major internal reorganization as the
parasite schizonts undergo massive expansion, with tens
of thousands of merozoites being made in each infected
cell. It is reasonable to speculate that in order to maxi-
mize the survival rate of the merozoites it would be
advantageous for the parasite to maintain structural
integrity of the host cell for as long as is feasibly possi-
ble. Construction of a dense cytoskeletal matrix formed
with crosslinked LSA-1 would be possible to create a
strong flexible cell that would allow rapid expansion but
minimize the chance of rupture. However, if this were
the case, why is LSA-1 protein not found in most other
Plasmodium species? It is possible that a similar floccu-
lent material seen in other Plasmodium species is func-
tionally analogous to LSA-1, but differs in sequence, and
a possible functional ortholog, identified by synteny
mapping [56] in Plasmodium berghei, that may play a
similar role.
It has recently been shown in P. berghei that mero-
zoites are released in ‘merosomes’ - clusters of mero-
zoites that bud off from the main hepatocyte, taking a
protective layer of the host membrane with them [29].
Prior to merosome formation, Plasmodium liver stages
seem to protect the host cell from apoptosis [57]
through hepatocyte growth factor (HGF) signaling of its
receptor MET, but may undergo autophagy induced by
the huge growth of the liver stage parasite [30]. HGF/
MET signaling may also occur during sporozoite inva-
sion of hepatocytes, again blocking apoptosis. LSA-1, or
analogous flocculent material, may therefore play a vital
role in maintaining cell integrity during autophagy and
merosome formation, TG2 has been shown to play an
essential role in conferring resistance to damage in the
liver [37]. Plasmodium falciparum may be using this
response to maintain the structural integrity of the
infected hepatocyte. Reinforcement of the cell by a LSA-
1 matrix could play a role in reducing the chance of
hepatocyte death by apoptosis.
These studies suggest that recombinant LSA-1 is a
TG2 substrate in vitro and that the unique modification
made by TG2 to the protein can be detected in vivo in a
pattern consistent with LSA-1 protein localization; this
is the first study suggesting a functional role for LSA-1.
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